Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

January 23rd 2025

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

January 23rd 2025

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC

January 23rd 2025

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

January 23rd 2025

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

Tagitanlimab Plus Chemotherapy Receives Chinese Approval for Recurrent/Metastatic Nasopharyngeal Cancer

January 23rd 2025

Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.

Dr Ghia on Potential Future Roles for Ibrutinib Plus Venetoclax in CLL

January 22nd 2025

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors

January 22nd 2025

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC

January 22nd 2025

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21st 2025

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

January 20th 2025

Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors.

Dr Hernandez-Ilizaliturri on Immunologic Changes in Venetoclax-Treated CLL

January 20th 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma

January 20th 2025

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

January 20th 2025

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

Health Canada Green Lights Fruquintinib for Metastatic Colorectal Cancer

January 20th 2025

Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

January 20th 2025

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

January 20th 2025

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

Development of LAVA-1207 Discontinues in mCRPC

January 20th 2025

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma

January 18th 2025

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes

January 17th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.